Epstein-Barr virus-associated post-transplant lymphoproliferative disease with central nervous system involvement after unrelated allogeneic hematopoietic stem cell transplantation

Leukemia and Lymphoma

Volumn 47, Issue 1, 2006, Pages 167-169

  Nozzoli, Chiara ^a   Bartolozzi, B ^a   Guidi, S ^a   Orsi, A ^b   Vannucchi, A M ^a   Leoni, F ^a   Bosi, A ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Cidofovir; CNS involvement; Epstein Barr virus reactivation; Intrathecal chemotherapy; Post transplant lymphoproliferative disorder; Rituximab

Indexed keywords

CIDOFOVIR; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FOSCARNET; GANCICLOVIR; METHOTREXATE; METHYLPREDNISOLONE; RITUXIMAB; STEROID; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CASE REPORT; CENTRAL NERVOUS SYSTEM DISEASE; CONFUSION; CYTOMEGALOVIRUS INFECTION; EPSTEIN BARR VIRUS; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA REMISSION; LYMPHADENOPATHY; LYMPHOPROLIFERATIVE DISEASE; MALE; MUSCLE WEAKNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; VIRUS REACTIVATION; WEIGHT REDUCTION; WHOLE BODY RADIATION;

ACUTE DISEASE; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM; EPSTEIN-BARR VIRUS INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID; LYMPHOPROLIFERATIVE DISORDERS; MALE; REMISSION INDUCTION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 30844439440     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500254208     Document Type: Article

References (13)

1. Curtis, R and Travis, L and Rowlings, P and Socie, G and Kingma, D and Banks, P and (1999) Risk of lymphoproliferative disorders after bone marrow transplantation: A multi-institutional study Blood, 94, pp. 2208-2216.
2. Juvonen, E and Aalto, S and Tarkkanen, J and Volin, L and Mattila, P and Knuutila, S and (2003) Post transplant lymphoproliferative disorder. High incidence of PTLD after non-T-cell-depleted allogeneic haematopoietic transplantation as a consequence of intensive immunosuppressive treatment Bone Marrow Transplant, 32, pp. 97-102.
3. Milpied, N and Vasseur, B and Parquet, N and Garnier, J and Antoine, C and Quartier, P and (2000) Humanized anti-CD20 monoclonal antibody (rituximab) in post transplant B-lymphoproliferative disorder: A retrospecitve analysis on 32 patients Ann Oncol, 11, pp. 113-116.
4. Comito, M and Sun, Q and Lucas, K. (2004) Immunotherapy for Epstein-Barr virus-associated tumors Leuk Lymphoma, 45, pp. 1981-1987.
5. Gruhn, B and Meerbach, A and Hüfer, R and Zell, R and Wutzler, P and Zintl, F. (2003) Pre-emptive therapy with rituximab for prevention of Epstein-Barr virus-associated lymphoproliferative diesase after hematopoietic stem cell transplantation Bone Marrow Transplant, 31, pp. 1023-1025.
6. Wagner, H and Cheng, Y and Huls, M and Gee, A and Kuehnle, I and Krance, R and (2004) Prompt versus preemptive intervention for EBV lymphoproliferative disease Blood, 103, pp. 3979-3981.
7. Leblond, V and Dhedin, N and Mamzer Bruneel, M and Bruneel, M and Choquet, S and (2001) Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders J Clin Oncol, 19, pp. 772-778.
8. Ifthikharuddin, J and Mieles, L and Rosenblatt, J and Ryan, C and Sahasrabudhe, D. (2000) CD-20 expression in post-transplant lymphoproliferative disorders: Treatment with rituximab Am J Haematol, 65, pp. 171-173.
9. Benkerrou, M and Jais, J and Leblond, V and Durandy, A and Sutton, L and Bordigoni, P and (1998) Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome Blood, 92, pp. 3137-3147.
10. Pakakasama, S and Eames, G and Morriss, M and Huls, M and Roonely, C and Heslop, H and (2004) Treatment of Epstein-Barr virus lymphoproliferative disease after hematopoietic stem-cell transplantation with hydroxyurea and cytotoxic T-cell lymphocytes Transplantation, 78, pp. 755-757.
11. Abdulkarim, B and Sabri, S and Zelenika, D and Deutsch, E and Frascogna, V and Klijanienko, J and (2003) Antiviral agent Cidofovir decreases Epstein-Barr virus (EBV) oncoproteins and enhances the radiosensitivity in EBV-related malignancies Oncogene, 22, pp. 2260-2271.
12. Hanel, M and Fiedler, F and Thorns, C. (2001) Anti-CD20 monoclonal antibody (Rituximab) and Cidofovir as successful treatment of an EBV-associated lymphoma with CNS involvement Onkologie, 24, pp. 491-494.
13. Chua, S and Seymour, J and Streater, J and Wolf, M and Januszewicz, E and Prince, H. (2002) Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma Leuk Lymphoma, 43, pp. 1783-1788.